A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD soluble WST11

Nacim Betrouni; Renaud Lopes; Philippe Puech; Pierre Colin; Serge Mordon

doi:10.1088/0031-9155/56/15/009

A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD soluble WST11

Nacim Betrouni, Renaud Lopes, Philippe Puech, Pierre Colin, Serge Mordon

Research output: Contribution to journal › Article › Scientific › peer-review

42 Citations (Scopus)

Abstract

Interstitial photodynamic therapy is becoming an interesting modality to treat some early stage prostate cancers. A light-sensitive drug is injected to the patient and activated by light using optical fibres inserted inside the prostate. In this work, we were interested in the characterization of the light action model for the WST11 (Tookad Soluble) drug. A retrospective analysis was performed on results from 28 patients enrolled in phase I and II trials with the WST11 drug. A drug dose of 4 mg/kg patient, dose light of 200 J cm^-1 and wavelength of 753 nm were used. Correlation between the illuminated volume and the obtained necrosis, measured at day 7 MR images, was clearly established. This result suggests that photodynamic therapy planning is possible based on this model.

Original language	English
Pages (from-to)	4771-4783
Number of pages	13
Journal	Physics in Medicine and Biology
Volume	56
Issue number	15
DOIs	https://doi.org/10.1088/0031-9155/56/15/009
Publication status	Published - 7 Aug 2011
Publication type	A1 Journal article-refereed

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1088/0031-9155/56/15/009

Cite this

@article{5e37d4a625544f38ab9b267cf3a668f7,

title = "A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD soluble WST11",

abstract = "Interstitial photodynamic therapy is becoming an interesting modality to treat some early stage prostate cancers. A light-sensitive drug is injected to the patient and activated by light using optical fibres inserted inside the prostate. In this work, we were interested in the characterization of the light action model for the WST11 (Tookad Soluble) drug. A retrospective analysis was performed on results from 28 patients enrolled in phase I and II trials with the WST11 drug. A drug dose of 4 mg/kg patient, dose light of 200 J cm-1 and wavelength of 753 nm were used. Correlation between the illuminated volume and the obtained necrosis, measured at day 7 MR images, was clearly established. This result suggests that photodynamic therapy planning is possible based on this model.",

author = "Nacim Betrouni and Renaud Lopes and Philippe Puech and Pierre Colin and Serge Mordon",

year = "2011",

month = aug,

day = "7",

doi = "10.1088/0031-9155/56/15/009",

language = "English",

volume = "56",

pages = "4771--4783",

journal = "Physics in Medicine and Biology",

issn = "0031-9155",

publisher = "IOP Publishing Ltd.",

number = "15",

}

TY - JOUR

T1 - A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD soluble WST11

AU - Betrouni, Nacim

AU - Lopes, Renaud

AU - Puech, Philippe

AU - Colin, Pierre

AU - Mordon, Serge

PY - 2011/8/7

Y1 - 2011/8/7

N2 - Interstitial photodynamic therapy is becoming an interesting modality to treat some early stage prostate cancers. A light-sensitive drug is injected to the patient and activated by light using optical fibres inserted inside the prostate. In this work, we were interested in the characterization of the light action model for the WST11 (Tookad Soluble) drug. A retrospective analysis was performed on results from 28 patients enrolled in phase I and II trials with the WST11 drug. A drug dose of 4 mg/kg patient, dose light of 200 J cm-1 and wavelength of 753 nm were used. Correlation between the illuminated volume and the obtained necrosis, measured at day 7 MR images, was clearly established. This result suggests that photodynamic therapy planning is possible based on this model.

AB - Interstitial photodynamic therapy is becoming an interesting modality to treat some early stage prostate cancers. A light-sensitive drug is injected to the patient and activated by light using optical fibres inserted inside the prostate. In this work, we were interested in the characterization of the light action model for the WST11 (Tookad Soluble) drug. A retrospective analysis was performed on results from 28 patients enrolled in phase I and II trials with the WST11 drug. A drug dose of 4 mg/kg patient, dose light of 200 J cm-1 and wavelength of 753 nm were used. Correlation between the illuminated volume and the obtained necrosis, measured at day 7 MR images, was clearly established. This result suggests that photodynamic therapy planning is possible based on this model.

UR - http://www.scopus.com/inward/record.url?scp=79961059627&partnerID=8YFLogxK

U2 - 10.1088/0031-9155/56/15/009

DO - 10.1088/0031-9155/56/15/009

M3 - Article

C2 - 21753234

AN - SCOPUS:79961059627

SN - 0031-9155

VL - 56

SP - 4771

EP - 4783

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

IS - 15

ER -

A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD soluble WST11

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this